dc.contributor.author | Tauraitė, Daiva | |
dc.contributor.author | Aučynaitė, Agota | |
dc.contributor.author | Meškys, Rolandas | |
dc.contributor.author | Urbonavičius, Jaunius | |
dc.date.accessioned | 2023-09-18T17:00:55Z | |
dc.date.available | 2023-09-18T17:00:55Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1742-464X | |
dc.identifier.uri | https://etalpykla.vilniustech.lt/handle/123456789/118944 | |
dc.description.abstract | Fluorinated derivatives of uracil and uridine can act as prodrugs in the cancer therapy. The chemical synthesis of 5-fluoroisocyto-sine and the fluorinated 20-O-methyluridine was performed. 5-Fluorouridine and 5-fluorodeoxyuridine were obtained by the enzymatic synthesis using thymidine phosphorylase (EC 2.4.2.4) from Escherichia coli. Thymidine phosphorylase mediates the nucleobase-exchange reaction to convert thymidine or uridine to modified nucleosides possessing a functional group at the 5th position and allows biosynthesis of modified nucleosides that are not possible to obtain by organic synthesis methods. The obtained compounds were converted into the 5-fluorouracil, a cancer drug, by action of newly discovered enzymes, such as iso-cytosine deaminase and nucleoside hydrolase. In conclusion, it was demonstrated that the synthesized fluorinated uracil derivatives could be used as prodrugs in the cancer therapy | eng |
dc.format | PDF | |
dc.format.extent | p. 341 | |
dc.format.medium | tekstas / txt | |
dc.language.iso | eng | |
dc.relation.isreferencedby | Science Citation Index Expanded (Web of Science) | |
dc.relation.isreferencedby | Conference Proceedings Citation Index - Science (Web of Science) | |
dc.source.uri | http://onlinelibrary.wiley.com/doi/10.1111/febs.14174/epdf | |
dc.subject | FM01 - Biokatalitinių procesų modeliavimas / Modelling of biocatalytic processes | |
dc.title | Synthesis of modified uracil derivatives and their potential use as prodrugs | |
dc.type | Konferencijos pranešimo santrauka tarptautinėse DB / Conference presentation abstract in an international DB | |
dcterms.accessRights | Meeting abstract: P.5.2-058 | |
dcterms.references | 0 | |
dc.type.pubtype | T1 - Konferencijos pranešimo tezės tarptautinėse DB / Conference presentation abstract in an international DB | |
dc.contributor.institution | Vilniaus Gedimino technikos universitetas Vilniaus universitetas | |
dc.contributor.institution | Vilniaus universitetas | |
dc.contributor.faculty | Fundamentinių mokslų fakultetas / Faculty of Fundamental Sciences | |
dc.subject.researchfield | T 005 - Chemijos inžinerija / Chemical engineering | |
dc.subject.researchfield | N 004 - Biochemija / Biochemistry | |
dc.subject.ltspecializations | L105 - Sveikatos technologijos ir biotechnologijos / Health technologies and biotechnologies | |
dc.subject.en | Prodrugs | |
dc.subject.en | Fluorinated | |
dc.subject.en | Chemical synthesis | |
dcterms.sourcetitle | FEBS Journal. 42nd Congress of the Federation-of-European-Biochemical-Societies (FEBS) on From Molecules to Cells and Back, Sep 10-14, 2017, Jerusalem, Israel | |
dc.description.issue | suppl. 1 | |
dc.description.volume | Vol. 284 | |
dc.publisher.name | Wiley | |
dc.publisher.city | New York, USA | |
dc.identifier.doi | 000409918904102 | |
dc.identifier.doi | 10.1111/febs.14174 | |
dc.identifier.elaba | 24484329 | |